Literature DB >> 10470099

Inverse correlation between apoptotic (Fas ligand, caspase-3) and angiogenic factors (VEGF, microvessel density) in squamous cell lung carcinomas.

M Volm1, J Mattern, R Koomägi.   

Abstract

In order to explore whether apoptosis is associated with angiogenesis in lung cancer, immunohistochemistry was employed to determine the pro-apoptotic factors Fas ligand (FasL) and caspase-3 (Cas-3) in 70 squamous cell lung carcinomas. Furthermore, the vascular endothelial growth factor (VEGF) and the microvessel density (MVD) were analyzed. The comparison between MVD and the pro-apoptotic factors demonstrated that the apoptotic factors are inversely related to MVD (Cas-3: p = 0.011, FasL: not significant). In order to confirm this result, FasL and Cas-3 were also compared with the expression of VEGF. Again, an inverse correlation between VEGF and the pro-apoptotic factors was found (Cas-3: p = 0.019, FasL: p = 0.008). The inverse correlation between angiogenesis and apoptosis may be explained by the activation of pro-apoptotic and anti-angiogenic factors caused by hypoxia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10470099

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  15 in total

1.  Immunohistochemical analysis of pro- and active-caspase 3 in laryngeal squamous cell carcinoma.

Authors:  Andrej Cör; Joze Pizem; Nina Gale
Journal:  Virchows Arch       Date:  2004-03-25       Impact factor: 4.064

Review 2.  Drug resistance in lung cancer.

Authors:  Manish Shanker; David Willcutts; Jack A Roth; Rajagopal Ramesh
Journal:  Lung Cancer (Auckl)       Date:  2010-05-08

3.  S100A4 gene silencing in oxygen-induced ischemic retinopathy inhibits retinal neovascularization via down-regulation of CREB expression.

Authors:  Gumeng Cheng; Kailin Tian; Lu Zhang; Ning Yang; Yiqiao Xing; Tao He
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-09-11       Impact factor: 3.117

4.  A VEGF/JAK2/STAT5 axis may partially mediate endothelial cell tolerance to hypoxia.

Authors:  Andrew C Dudley; David Thomas; James Best; Alicia Jenkins
Journal:  Biochem J       Date:  2005-09-01       Impact factor: 3.857

5.  VEGF165 antisense RNA suppresses oncogenic properties of human esophageal squamous cell carcinoma.

Authors:  Zhong-Ping Gu; Yun-Jie Wang; Jin-Ge Li; Yong-An Zhou
Journal:  World J Gastroenterol       Date:  2002-02       Impact factor: 5.742

6.  Procaspase-3 Overexpression in Cancer: A Paradoxical Observation with Therapeutic Potential.

Authors:  Matthew W Boudreau; Jessie Peh; Paul J Hergenrother
Journal:  ACS Chem Biol       Date:  2019-07-16       Impact factor: 5.100

7.  Relationship of 99mTc-HYNIC annexin V uptake to microvessel density, FasL and MMP-9 expression, and the number of tumour-infiltrating lymphocytes in head and neck carcinoma.

Authors:  Hubert Vermeersch; Kris Mervillie; Christophe Lahorte; David Loose; Rudi Andre Dierck; Neil Steinmetz; Claude Cuvelier; Guido Slegers; Christophe Van de Wiele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-03-11       Impact factor: 9.236

8.  Human Umbilical Cord Matrix Stem Cells Reverse Oxidative Stress-Induced Cell Death and Ameliorate Motor Function and Striatal Atrophy in Rat Model of Huntington Disease.

Authors:  Mohammad Javad Ebrahimi; Abbas Aliaghaei; Mahdi Eskandarian Boroujeni; Fariba Khodagholi; Gholamhoussein Meftahi; Mohammad Amin Abdollahifar; Houssein Ahmadi; Samira Danyali; Mahtab Daftari; Yousef Sadeghi
Journal:  Neurotox Res       Date:  2018-03-08       Impact factor: 3.911

9.  Differential activity of caspase-3 regulates susceptibility of lung and breast tumor cell lines to Paclitaxel.

Authors:  Charles Amoatey Odonkor; Samuel Achilefu
Journal:  Open Biochem J       Date:  2008-09-27

10.  Soluble Fas ligand inhibits angiogenesis in rheumatoid arthritis.

Authors:  Wan-Uk Kim; Seung-Ki Kwok; Kyung-Hee Hong; Seung-Ah Yoo; Jin-Sun Kong; Jongseon Choe; Chul-Soo Cho
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.